NEXUS AG: Substantial Increase in Sales and Result in the First Half-Year 2015

Villingen-Schwenningen, 18 August 2015: NEXUS AG, specialized in hospital software, was able to increase sales by 24.4 % and its result before taxes and interest (EBIT) by 19.6 % in the first half-year 2015. As a result, the long-term and sustainable positive development of NEXUS Group of recent years could be continued.

Sales increased by approx. 24.4 % from KEUR 37,823 (1st HY 2014) to KEUR 47,051 in the first half-year 2015. In the Healthcare Software Division, sales increased by 29.3 % and reached KEUR 43,454 (1st HY 2014: KEUR 33,602). The Healthcare Service Division had sales of KEUR 3,597 in the first six months 2015 following KEUR 4,221 (1st HY 2014) and was thus 14.8 % below the previous year. The international share of total business volume was 50.6 % in the first half-year (1st HY 2014: 40.8 %) and amounted to KEUR 23,787 following KEUR 15,447 in the previous year. The sales of the subsidiary NEXUS Nederland consolidated for the first time are included in the figures. The change of the Swiss franc exchange rate against the euro also had a positive effect on sales development (KEUR 1,785).

Earnings before interest and taxes (EBIT) in the amount of KEUR 4,284 improved compared to the same period last year by 19.6 % (1st HY 2014: KEUR 3,581). The EBITA rose very significantly by 86.8 % from KEUR 4,441 (1st HY 2014) to KEUR 8,295. The EBITDA recorded an increase of 29.4 % to KEUR 8,923 (1st HY 2014: KEUR 6,898) in the reporting period.

The operative cash flow developed particularly strongly in the first half of 2015, which reached KEUR 10,924 following KEUR 5,064 (1st HY 2014) reached (+115.7 %). Dividends in the amount of KEUR 1,961 (previous year: KEUR 1,808) have been paid in the half-year 2015. The company has cash resources in the amount of KEUR 20,529 (1st HY 2014: KEUR 24,911).

NEXUS AG has equity capital amounting to KEUR 88,791. As a result, NEXUS AG has a sustainable and healthy balance sheet as well as sufficient capital for further financing of its European growth strategy.